A Phase II Trial of Everolimus for Cancer Patients With Inactivating Mutations in TSC1 or TSC2 or Activating MTOR Mutations
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2019
Price : $35 *
At a glance
- Drugs Everolimus (Primary)
- Indications Tuberous sclerosis
- Focus Therapeutic Use
- 05 Nov 2019 Status changed from active, no longer recruiting to completed.
- 01 Nov 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Jun 2019.
- 01 Nov 2018 Status changed from recruiting to active, no longer recruiting.